GMOV - ETF AI Analysis
Top Page
GMO US Value ETF (GMOV)
Rating:73Outperform
Price Target:―
Positive Factors
Broad Sector Diversification
The ETF spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.
Generally Strong Recent Performance
The fund has shown solid gains over the past month, three months, and year to date, indicating positive recent momentum.
Several Strong Top Holdings
Many of the largest positions, such as Exxon Mobil, Johnson & Johnson, Pfizer, and Verizon, have delivered strong year-to-date results that support the fund’s overall performance.
Negative Factors
High U.S. Concentration
With almost all assets in U.S. stocks, the ETF offers very little geographic diversification and is heavily tied to the U.S. market.
Mixed Performance Among Top Holdings
Some key positions, including Bank of America and Qualcomm, have shown weak year-to-date performance, which can drag on the fund’s returns.
Moderate Expense Ratio
The fund’s expense ratio is not especially low, meaning fees take a noticeable, ongoing bite out of investor returns compared with cheaper ETFs.
GMOV vs. SPDR S&P 500 ETF (SPY)
AUM99.59M
RegionNorth America
Expense Ratio0.50%
Beta0.69
IssuerGMO
Inception DateOct 28, 2024
Dividend Yield1.9%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume25,931
30 Day Avg. Volume17,541
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
35.58Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering165
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GMOV Summary
GMOV is the GMO US Value ETF, which invests in a wide range of U.S. stocks with a focus on companies that appear undervalued. It doesn’t track a specific index, but follows a value-investing theme across many sectors like financials, health care, and communication services. Well-known holdings include Meta Platforms and Alphabet (Google), along with large health care and energy companies. Someone might invest in GMOV to diversify across the U.S. market while tilting toward cheaper, potentially overlooked stocks. A key risk is that value stocks can stay out of favor for long periods, so the price can go up and down with market swings.
How much will it cost me?The GMO US Value ETF (GMOV) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, relying on expert analysts to select undervalued stocks with strong growth potential.
What would affect this ETF?The GMO US Value ETF could benefit from a favorable economic environment that supports undervalued stocks, particularly in sectors like Financials and Health Care, which are heavily represented in its portfolio. However, rising interest rates or regulatory changes in key sectors such as Technology and Energy could negatively impact the ETF's performance. Additionally, shifts in consumer spending or market sentiment might influence the value of top holdings like Johnson & Johnson and Meta Platforms.
GMOV Top 10 Holdings
GMOV leans heavily into classic U.S. value, with a clear tilt toward financials and old-guard blue chips rather than flashy growth names. Microsoft and Meta have been losing steam lately, acting as a bit of a headwind despite their tech heft. Offsetting that, Exxon Mobil, Merck, and Johnson & Johnson are quietly pulling their weight, helped by steady energy and healthcare trends. Verizon and Bank of America add to the value flavor, making this a U.S.-only portfolio that bets more on solid balance sheets than on headline-grabbing momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Meta Platforms | 6.35% | $6.32M | $1.64T | -8.27% | 76 Outperform | |
| Microsoft | 5.75% | $5.72M | $2.93T | -22.79% | 79 Outperform | |
| Exxon Mobil | 3.53% | $3.51M | $610.73B | 36.74% | 74 Outperform | |
| Merck & Company | 2.80% | $2.78M | $314.90B | 59.45% | 80 Outperform | |
| JPMorgan Chase | 2.51% | $2.50M | $913.98B | 17.11% | 72 Outperform | |
| Verizon | 2.34% | $2.33M | $182.01B | 6.73% | 81 Outperform | |
| Pfizer | 2.23% | $2.22M | $142.77B | 2.37% | 74 Outperform | |
| Johnson & Johnson | 2.12% | $2.11M | $609.12B | 54.58% | 78 Outperform | |
| Procter & Gamble | 2.10% | $2.09M | $349.24B | -3.30% | 69 Neutral | |
| Bank of America | 2.06% | $2.05M | $434.81B | 29.48% | 72 Outperform |
GMOV Technical Analysis
Positive
―
Price Trends
30.03
Positive
29.26
Positive
28.14
Positive
Market Momentum
0.30
Negative
64.84
Neutral
84.19
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GMOV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.28, equal to the 50-day MA of 30.03, and equal to the 200-day MA of 28.14, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 64.84 is Neutral, neither overbought nor oversold. The STOCH value of 84.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GMOV.
GMOV Peer Comparison
Comparison Results
Performance Comparison
GMOV
GMO US Value ETF
31.05
6.42
26.07%
SASS
M.D. Sass Concentrated Value ETF
―
―
―
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
GVLE
Goldman Sachs Value Opportunities ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
USFE
First Eagle US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents